EGFR and non-small cell lung carcinoma: Gefitinib [2], erlotinib [3] and, more recently, afatinib [5], are the only three TKIs approved for the first-line treatment of EGFR-mutated advanced NSCLC, which represents about 10%–15% of all NSCLC.